Biopharmaceutical company BioVaxys Technology Corp (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) and SpayVac for Wildlife Inc, a developer of humane fertility-control vaccines for animals, on Wednesday announced the successful scaling-up of vaccine production at SpayVac's Madison, Wisconsin facility.

This expanded capacity enables production of SpayVac's proprietary contraceptive vaccines, including the established pZP vaccine and the new GnRH vaccine for aquaculture and wildlife applications.

The increased output supports upcoming field trials, market seeding studies and preparations for broader vaccine launches. Recent shipments include a large-scale delivery for a European feral horse management project and earlier production for immunocontraception initiatives in Southeast Asia.

SpayVac employs a patented liposome-based antigen delivery platform licensed from BioVaxys, offering single-dose, multi-year fertility control for various species. Future plans involve further scaling production to meet global demand for tens of thousands of doses.

BioVaxys is concurrently advancing its immunotherapy programs for human applications, including infectious diseases, oncology and allergy. Its pipeline features the DPX platform and HapTenix technology, with multiple candidates in clinical development, such as maveropepimut-S (MVP-S) for advanced cancers and DPX-RSV for respiratory diseases.